Laboratories advised to look out for tuberculosis false-positives
This article was originally published in Clinica
Tuberculosis control programmes should always be on the lookout for clusters of false-positive diagnoses in the data they analyse, advises the US Centers for Disease Control. The CDC's Mortality and Morbidity Weekly Report on August 29 analyses a series of five incidents in which 11 patients were misdiagnosed as having TB.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.